{"id":7845,"date":"2025-03-20T17:45:00","date_gmt":"2025-03-20T16:45:00","guid":{"rendered":"https:\/\/intrasense.fr\/?post_type=actualite&#038;p=7845"},"modified":"2025-03-25T15:25:07","modified_gmt":"2025-03-25T14:25:07","slug":"us-food-and-drug-administration-fda-grants-breakthrough-device-status-to-guerbet-innovation-duonco-pancreas-for-early-detection-of-pancreatic-lesions","status":"publish","type":"actualite","link":"https:\/\/intrasense.fr\/en\/actualite\/us-food-and-drug-administration-fda-grants-breakthrough-device-status-to-guerbet-innovation-duonco-pancreas-for-early-detection-of-pancreatic-lesions\/","title":{"rendered":"US Food and Drug Administration (FDA) grants Breakthrough Device status to Guerbet innovation: DUOnco Pancreas for early detection of pancreatic lesions"},"content":{"rendered":"\n<p>Guerbet (FR0000032526 GBT), a world leader in medical imaging solutions, today announced that the US Food and Drug Administration (FDA) has granted \u201cBreakthrough Device\u201d designation to DUOnco<sup>TM<\/sup> Pancreas for which Intrasense (ISIN: FR0011179886 - Mnemo: ALINS), a French expert in AI-enhanced medical imaging solutions facilitating and securing diagnosis, decision-making and therapeutic follow-up, will be the legal manufacturer.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Guerbet (FR0000032526 GBT), a world leader in medical imaging solutions, today announced that the US Food and Drug Administration (FDA) has granted \u201cBreakthrough Device\u201d designation to DUOncoTM Pancreas for which Intrasense (ISIN: FR0011179886 - Mnemo: ALINS), a French expert in AI-enhanced medical imaging solutions facilitating and securing diagnosis, decision-making and therapeutic follow-up, will be the [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"template":"","categories":[83],"class_list":["post-7845","actualite","type-actualite","status-publish","hentry","category-press-releases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>US Food and Drug Administration (FDA) grants Breakthrough Device status to Guerbet innovation: DUOnco Pancreas for early detection of pancreatic lesions - Intrasense<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/intrasense.fr\/en\/actualite\/us-food-and-drug-administration-fda-grants-breakthrough-device-status-to-guerbet-innovation-duonco-pancreas-for-early-detection-of-pancreatic-lesions\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"US Food and Drug Administration (FDA) grants Breakthrough Device status to Guerbet innovation: DUOnco Pancreas for early detection of pancreatic lesions - Intrasense\" \/>\n<meta property=\"og:description\" content=\"Guerbet (FR0000032526 GBT), a world leader in medical imaging solutions, today announced that the US Food and Drug Administration (FDA) has granted \u201cBreakthrough Device\u201d designation to DUOncoTM Pancreas for which Intrasense (ISIN: FR0011179886 - Mnemo: ALINS), a French expert in AI-enhanced medical imaging solutions facilitating and securing diagnosis, decision-making and therapeutic follow-up, will be the [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/intrasense.fr\/en\/actualite\/us-food-and-drug-administration-fda-grants-breakthrough-device-status-to-guerbet-innovation-duonco-pancreas-for-early-detection-of-pancreatic-lesions\/\" \/>\n<meta property=\"og:site_name\" content=\"Intrasense\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-25T14:25:07+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/intrasense.fr\\\/en\\\/actualite\\\/us-food-and-drug-administration-fda-grants-breakthrough-device-status-to-guerbet-innovation-duonco-pancreas-for-early-detection-of-pancreatic-lesions\\\/\",\"url\":\"https:\\\/\\\/intrasense.fr\\\/en\\\/actualite\\\/us-food-and-drug-administration-fda-grants-breakthrough-device-status-to-guerbet-innovation-duonco-pancreas-for-early-detection-of-pancreatic-lesions\\\/\",\"name\":\"US Food and Drug Administration (FDA) grants Breakthrough Device status to Guerbet innovation: DUOnco Pancreas for early detection of pancreatic lesions - Intrasense\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/intrasense.fr\\\/fr\\\/#website\"},\"datePublished\":\"2025-03-20T16:45:00+00:00\",\"dateModified\":\"2025-03-25T14:25:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/intrasense.fr\\\/en\\\/actualite\\\/us-food-and-drug-administration-fda-grants-breakthrough-device-status-to-guerbet-innovation-duonco-pancreas-for-early-detection-of-pancreatic-lesions\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/intrasense.fr\\\/en\\\/actualite\\\/us-food-and-drug-administration-fda-grants-breakthrough-device-status-to-guerbet-innovation-duonco-pancreas-for-early-detection-of-pancreatic-lesions\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/intrasense.fr\\\/en\\\/actualite\\\/us-food-and-drug-administration-fda-grants-breakthrough-device-status-to-guerbet-innovation-duonco-pancreas-for-early-detection-of-pancreatic-lesions\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/intrasense.fr\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"US Food and Drug Administration (FDA) grants Breakthrough Device status to Guerbet innovation: DUOnco Pancreas for early detection of pancreatic lesions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/intrasense.fr\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/intrasense.fr\\\/fr\\\/\",\"name\":\"Intrasense\",\"description\":\"A website using WP\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/intrasense.fr\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"US Food and Drug Administration (FDA) grants Breakthrough Device status to Guerbet innovation: DUOnco Pancreas for early detection of pancreatic lesions - Intrasense","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/intrasense.fr\/en\/actualite\/us-food-and-drug-administration-fda-grants-breakthrough-device-status-to-guerbet-innovation-duonco-pancreas-for-early-detection-of-pancreatic-lesions\/","og_locale":"en_US","og_type":"article","og_title":"US Food and Drug Administration (FDA) grants Breakthrough Device status to Guerbet innovation: DUOnco Pancreas for early detection of pancreatic lesions - Intrasense","og_description":"Guerbet (FR0000032526 GBT), a world leader in medical imaging solutions, today announced that the US Food and Drug Administration (FDA) has granted \u201cBreakthrough Device\u201d designation to DUOncoTM Pancreas for which Intrasense (ISIN: FR0011179886 - Mnemo: ALINS), a French expert in AI-enhanced medical imaging solutions facilitating and securing diagnosis, decision-making and therapeutic follow-up, will be the [&hellip;]","og_url":"https:\/\/intrasense.fr\/en\/actualite\/us-food-and-drug-administration-fda-grants-breakthrough-device-status-to-guerbet-innovation-duonco-pancreas-for-early-detection-of-pancreatic-lesions\/","og_site_name":"Intrasense","article_modified_time":"2025-03-25T14:25:07+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/intrasense.fr\/en\/actualite\/us-food-and-drug-administration-fda-grants-breakthrough-device-status-to-guerbet-innovation-duonco-pancreas-for-early-detection-of-pancreatic-lesions\/","url":"https:\/\/intrasense.fr\/en\/actualite\/us-food-and-drug-administration-fda-grants-breakthrough-device-status-to-guerbet-innovation-duonco-pancreas-for-early-detection-of-pancreatic-lesions\/","name":"US Food and Drug Administration (FDA) grants Breakthrough Device status to Guerbet innovation: DUOnco Pancreas for early detection of pancreatic lesions - Intrasense","isPartOf":{"@id":"https:\/\/intrasense.fr\/fr\/#website"},"datePublished":"2025-03-20T16:45:00+00:00","dateModified":"2025-03-25T14:25:07+00:00","breadcrumb":{"@id":"https:\/\/intrasense.fr\/en\/actualite\/us-food-and-drug-administration-fda-grants-breakthrough-device-status-to-guerbet-innovation-duonco-pancreas-for-early-detection-of-pancreatic-lesions\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/intrasense.fr\/en\/actualite\/us-food-and-drug-administration-fda-grants-breakthrough-device-status-to-guerbet-innovation-duonco-pancreas-for-early-detection-of-pancreatic-lesions\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/intrasense.fr\/en\/actualite\/us-food-and-drug-administration-fda-grants-breakthrough-device-status-to-guerbet-innovation-duonco-pancreas-for-early-detection-of-pancreatic-lesions\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/intrasense.fr\/en\/"},{"@type":"ListItem","position":2,"name":"US Food and Drug Administration (FDA) grants Breakthrough Device status to Guerbet innovation: DUOnco Pancreas for early detection of pancreatic lesions"}]},{"@type":"WebSite","@id":"https:\/\/intrasense.fr\/fr\/#website","url":"https:\/\/intrasense.fr\/fr\/","name":"Intrasense","description":"A website using WP","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/intrasense.fr\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/intrasense.fr\/en\/wp-json\/wp\/v2\/actualite\/7845","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/intrasense.fr\/en\/wp-json\/wp\/v2\/actualite"}],"about":[{"href":"https:\/\/intrasense.fr\/en\/wp-json\/wp\/v2\/types\/actualite"}],"author":[{"embeddable":true,"href":"https:\/\/intrasense.fr\/en\/wp-json\/wp\/v2\/users\/2"}],"wp:attachment":[{"href":"https:\/\/intrasense.fr\/en\/wp-json\/wp\/v2\/media?parent=7845"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/intrasense.fr\/en\/wp-json\/wp\/v2\/categories?post=7845"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}